Business Description
InflaRx NV
NAICS : 541720
SIC : 2834
ISIN : NL0012661870
Total Employee Number:
65Description
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 48.38 | |||||
Equity-to-Asset | 0.76 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.02 | |||||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | 1.71 | |||||
Beneish M-Score | -1.77 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -4.4 | |||||
3-Year EPS without NRI Growth Rate | 1.7 | |||||
3-Year FCF Growth Rate | 8.7 | |||||
3-Year Book Growth Rate | -31.5 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 296.86 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 85.95 | |||||
9-Day RSI | 72.23 | |||||
14-Day RSI | 63.79 | |||||
3-1 Month Momentum % | 167.78 | |||||
6-1 Month Momentum % | 137.13 | |||||
12-1 Month Momentum % | 203.16 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.16 | |||||
Quick Ratio | 4.16 | |||||
Cash Ratio | 3.49 | |||||
Days Inventory | 285.32 | |||||
Days Payable | 371.46 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -17.4 | |||||
Shareholder Yield % | -0.01 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | -25524.24 | |||||
Operating Margin % | -149403.03 | |||||
Net Margin % | -151348.49 | |||||
EBITDA Margin % | -149424.24 | |||||
FCF Margin % | -101548.48 | |||||
OCF Margin % | -101148.48 | |||||
ROE % | -87.15 | |||||
ROA % | -66.34 | |||||
ROIC % | -376.54 | |||||
3-Year ROIIC % | 385.6 | |||||
ROC (Joel Greenblatt) % | -2716.19 | |||||
ROCE % | -85.94 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 2240 | |||||
PB Ratio | 3.8 | |||||
Price-to-Tangible-Book | 3.79 | |||||
EV-to-EBIT | -5.74 | |||||
EV-to-Forward-EBIT | -6.46 | |||||
EV-to-EBITDA | -5.79 | |||||
EV-to-Forward-EBITDA | -6.46 | |||||
EV-to-Revenue | 8653.03 | |||||
EV-to-Forward-Revenue | 8207.57 | |||||
EV-to-FCF | -8.52 | |||||
| Price-to-Net-Current-Asset-Value | 3.92 | |||||
| Price-to-Net-Cash | 5.08 | |||||
Earnings Yield (Greenblatt) % | -17.42 | |||||
FCF Yield % | -10.16 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:IFRX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
InflaRx NV Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.033 | ||
| EPS (TTM) ($) | -0.721 | ||
| Beta | 3.6098 | ||
| 3-Year Sharpe Ratio | 0.28 | ||
| 3-Year Sortino Ratio | 0.59 | ||
| Volatility % | 154.55 | ||
| 14-Day RSI | 63.79 | ||
| 14-Day ATR ($) | 0.208354 | ||
| 20-Day SMA ($) | 1.866 | ||
| 12-1 Month Momentum % | 203.16 | ||
| 52-Week Range ($) | 0.7406 - 2.9489 | ||
| Shares Outstanding (Mil) | 147.29 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
InflaRx NV Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
InflaRx NV Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-10 | In 132 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 37 days | ||
| First quarter earnings results for 2026 | 2026-05-07 | 2.50 (-1.96%) | ||
| Annual report for 2025 | 2026-03-20 | 0.91 (+4.55%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-19 | 0.88 (-11.21%) | ||
| Leerink Partners Global Healthcare Conference | 2026-03-09 09:20 | 0.97 (+6.59%) | ||
| Oppenheimer 36th Annual Healthcare Life Sciences Conference | 2026-02-25 08:40 | 0.88 (+0.22%) | ||
| Guidance call for 2026 | 2026-02-11 11:30 | 0.84 (-0.60%) | ||
| Guggenheim Securities 2nd Annual Healthcare Innovation Conference | 2025-11-11 14:30 | 1.58 (-10.73%) | ||
| Third quarter earnings results for 2025 | 2025-11-10 | 1.23 (+3.36%) |
Show
Entries
InflaRx NV Frequently Asked Questions
What is InflaRx NV(IFRX)'s stock price today?
The current price of IFRX is $2.24. The 52 week high of IFRX is $2.95 and 52 week low is $0.74.
When is next earnings date of InflaRx NV(IFRX)?
The next earnings date of InflaRx NV(IFRX) is 2026-08-07 Est..
Does InflaRx NV(IFRX) pay dividends? If so, how much?
InflaRx NV(IFRX) does not pay dividend.
Guru Commentaries on NAS:IFRX
No articles.
Press Release
Articles on InflaRx NV
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers